Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Exclusion criteria

• . Diagnosis of other malignant diseases other than non-small cell lung cancer within 5 years before the first administration (excluding radically cured skin basal cell carcinoma, skin squamous epithelial carcinoma and/or radically excised carcinoma in situ);
• . Currently participating in interventional clinical research treatment, or received other research drugs or used research devices within 4 weeks before the first administration;
• . Received anti-tumor drug treatment (including Chinese herbal medicine with anti-tumor indications) within 28 days before using the first administration;
• . Before starting treatment, have not fully recovered from toxicity and/or complications caused by any intervention (ie, ≤ Grade 1 or reached baseline, excluding fatigue or hair loss) ;
• . Meningeal metastasis/cancerous meningitis or central nervous system metastasis with known symptoms. For asymptomatic participants or participants with stable brain metastases after local treatment, those participants are also allowed to join the group if the following conditions are met :1) There are measurable lesions outside the central nervous system; 2) No symptoms of the central nervous system or no aggravation of symptoms within at least 2 weeks; 3) There is no evidence of imaging progress at least 4 weeks before the first administration; 4) Those who do not need glucocorticoid therapy or stop glucocorticoid therapy within 14 days before the first study drug administration;
• . There is clinically uncontrollable pleural effusion/abdominal effusion (patients who do not need to drain the effusion or stop drainage for 3 days without a significant increase in effusion can be included);
• . Known human immunodeficiency virus (HIV) infection history or confirmed positive immunological test results;
• . Acute or chronic active hepatitis B (defined as HBsAg positive and the HBV-DNA copy number is greater than the upper limit of the normal value of the laboratory department of the research center), active hepatitis C (HCV) infection (defined as HCV antibody positive and Patients whose HCV-RNA level is higher than the lower limit of detection), or patients with both hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive at the same time. Note: Hepatitis B participant who meet the following criteria can also be included in the group:1) Before the first administration, the HBV viral load is less than 1000 copies/ml (200 IU/ml), and the participant should receive anti-HBV treatment during the entire study drug treatment period to avoid viral reactivation 2) For participants with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), there is no need to receive preventive anti-HBV treatment, but close monitoring of virus reactivation is required.